AURINIA PHARMACEUTICALS TO RELEASE FIRST QUARTER 2018 FINANCIAL RESULTS ON MAY 10, 2018
Aurinia Pharmaceuticals Inc. will release its first quarter 2018 financial results on
May 10, 2018, after the market closes. Aurinia's management
will host a conference call to discuss the company's first quarter 2018
financial results and provide a general business update.
The conference call and webcast are scheduled for May 10, 2018, at 4:30 p.m.
EDT. To participate in the conference call, please dial
1-877-407-9170 (toll-free United States and Canada). An audio webcast can be
accessed under news/events through the investors section of the
Aurinia corporate website. A replay of the webcast will be available on Aurinia's website.
Aurinia is a clinical-stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of LN, FSGS and DES. The company is headquartered in Victoria,
B.C., and focuses its development efforts globally.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.